Scrip

Array Raring To Go Commercially With First Approval – Mektovi/Braftovi

27 Jun 2018

• By Emily Hayes

Array believes that a zero copay offer for patients will help its newly FDA-approved Mektovi/Braftovi combination stand out from the crowd in melanoma and notes that the regimen also has potential in a larger indication – colon cancer.

The US FDA approved Array Biopharma Inc.’s MEK inhibitor Mektovi (binimetinib) and BRAF inhibitor Braftovi (encorafenib) for combination treatment of metastatic melanoma on June 27. This marks Array Biopharma's transition into a commercial enterprise, and the company has been preparing to launch immediately.

Prior to approval, it had already put 60 customer facing team members in place, including representatives working with prescribers and...